Straits Times Index
3,314.14 +8.12 (+0.25%) S&P 500
5,464.62 -8.55 (-0.16%) Dow
39,150.33 +15.53 (+0.04%) Nasdaq
17,689.36 -32.24 (-0.18%) Bitcoin USD
61,129.23 -3,143.72 (-4.89%) CMC Crypto 200
1,257.22 -52.50 (-4.01%)
Sartorius Stedim Biotech S.A. (0RG8.L)
Sartorius Stedim Biotech S.A.
Zone Industrielle Les Paluds
Avenue de Jouques – CS 91051 Cedex
Aubagne 13781
France
33 4 42 84 56 00
https://www.sartorius.com
Sector(s):
Industry:
Full-time employees: 10,493
Description
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.
Corporate governance
Sartorius Stedim Biotech S.A.’s ISS governance QualityScore as of 1 June 2024 is 6. The pillar scores are Audit: 3; Board: 4; Shareholder rights: 8; Compensation: 8.
